Alex Rosen
Direktor/Vorstandsmitglied bei Upstream Bio, Inc.
Profil
Alex Rosen is currently working as a Director at Upstream Bio, Inc. Prior to this, he worked as a Biotech Investor at Venrock Associates.
Mr. Rosen holds a doctorate degree from the University of Pennsylvania, an undergraduate degree from Princeton University, and an MBA from The Wharton School of the University of Pennsylvania.
Aktive Positionen von Alex Rosen
Unternehmen | Position | Beginn |
---|---|---|
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Direktor/Vorstandsmitglied | 08.06.2023 |
Ehemalige bekannte Positionen von Alex Rosen
Unternehmen | Position | Ende |
---|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Private Equity Investor | - |
Ausbildung von Alex Rosen
The Wharton School of the University of Pennsylvania | Masters Business Admin |
University of Pennsylvania | Doctorate Degree |
Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |